Dermasonics reduces manufacturing costs of needle-free drug-injection
12 May 2006
Irvine, Calif., USA. Dermisonics, Inc. (Bulletin Board:
DMSI.OB) has reduced the manufacturing costs of the ultrasonic
transducer for its needle-free and painless drug injection device. This will
make the devices more affordable for consumer use.
The company has
completed a demonstration of a mass production system for the specialised
ultrasonic transducers used in its U-Strip ultrasonic drug-delivery
The U-Strip patented electronic system uses a specialized form
of ultrasound waves to enhance the delivery of drugs through the skin and
into the bloodstream from a specially modified patch. Ultrasound is
generated via transducers, which convert electronic signals into mechanical
energy. The transducers used in the U-Strip design emit an alternating
ultrasonic waveform, sawtooth to squarewave, as opposed to ordinary
transducers, which emit only sine waves, and generate a tremendous amount of
heat energy as a result. The alternating signal reduces the heating effect,
which could damage a drug in a transdermal patch delivery system.
recently these transducers were hand made to exacting specifications.
Dermisonics engineers have produced a manufacturing mold system, which can
fabricate the Redding Generation-5 transducers, on an assembly line basis.
This step is expected to dramatically improve transducer precision and
anticipated to reduce manufacturing costs.
Inventor of Dermisonics'
technology and Executive VP, Bruce Redding states, "The mass production
process for the Redding Generation-5 transducers significantly improves our
cost structure on what is the most expensive component of the U-strip System
and puts the system in a range more suitable for both our consumer products
and our drug delivery applications." Redding adds. "In order to enable the
wide adoption of our technology, it will be necessary to prepare for the
mass production of its components. Production capability of the U-Strip
transducer devices is now in place."
Dermisonics is currently recruiting
recipients to proceed with a planned Human Pilot Trial-2 on its U-Strip
delivery system for use with insulin on type-2 adult diabetics.